ErVaccine announced a collaboration with two companies
June 1, 2022

ErVaccine announced a collaboration with two US companies: EVOQ Therapeutics, for the development of synthetic HDL NanoDiscs to deliver cancer vaccine candidates and Oncovir for the rights to use their immune adjuvant Hiltonol to run an evaluation study. Over this agreement, ErVaccine will assess the interest of combining innovative tumor antigens, a breakthrough delivery technology and a potent adjuvant with the aim of enhancing vaccine-induced antitumor immune responses.

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice

Navigation

> Home

> About us

> Sciences

> Investors

> Join us

> Contact

Contact

28 RUE LAENNEC
69008 
LYON FRANCE

contact@ervimmune.com

+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go